Publication:
The effects of topical prophylthiouracyl in plaque type psoriasis: A prospective, double-blind, placebo-controlled study

dc.contributor.authorToker, Semra Çıkman
dc.contributor.authorSarıcaoğlu, Hayriye
dc.contributor.authorAdım, Şaduman Balaban
dc.contributor.authorBaşkan, Emel Bülbül
dc.contributor.authorKaradoğan, Serap Koran
dc.contributor.authorTunalı, Şükran
dc.contributor.buuauthorToker, Semra Çıkman
dc.contributor.buuauthorSARICAOĞLU, HAYRİYE
dc.contributor.buuauthorBALABAN ADIM, ŞADUMAN
dc.contributor.buuauthorBÜLBÜL BAŞKAN, EMEL
dc.contributor.buuauthorKaradoğan, Serap Koran
dc.contributor.buuauthorTunalı, Şükran
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentPatoloji Ana Bilim Dalı
dc.contributor.researcheridAAH-1388-2021
dc.contributor.researcheridAAH-6216-2021
dc.contributor.researcheridCBU-2730-2022
dc.contributor.researcheridDPU-8534-2022
dc.contributor.researcheridEMN-0789-2022
dc.contributor.researcheridGGH-7385-2022
dc.date.accessioned2024-11-18T05:42:49Z
dc.date.available2024-11-18T05:42:49Z
dc.date.issued2005-01-01
dc.description.abstractBackground and Design: Propylthiouracil (PTU) decreases the synthesis of thyroid hormon as well as having immune modulatory and free radical scavenging effects. Oral PTU has been shown to be effective for the treatment of plaque psoriasis in several studies. This study was performed to determine the efficacy of topical PTU in psoriasis.Materials and Methods: Different plaques of 16 patients with plaque psoriasis were treated with 5% topical PTU and placebo, three times daily for 8 weeks in a setting of a double-blind and placebo controlled study. Response to therapy was evaluated by using clinical score, histopathologic score and epidermal thickness.Results: The clinical scores of both PTU and placebo plaques decreased significantly after the treatment (p<0.001). The epidermal thickness of the psoriatic PTU plaques before and after treatment were 0.57 +/- 0.1 mm and 0.46 +/- 0.19 mm, respectively. Furthermore, no significant difference was observed between the pre- and post-treatment histopathological findings of plaques treated with PTU.Conclusion: Topical PTU may be viable steroid-sparing agent, since topical corticosteroid as a conventional agent, have many side effects. Since we didn't observe a significant difference between the plaques treated with PTU and placebo in our group, we concluded that further studies with larger series should be performed to confirm this hypothesis.
dc.identifier.eissn1308-6294
dc.identifier.endpage259
dc.identifier.issn1019-214X
dc.identifier.issue4
dc.identifier.startpage255
dc.identifier.urihttps://hdl.handle.net/11452/47955
dc.identifier.volume39
dc.identifier.wos000217247100005
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherTürk Sosyoloji Dermatoloji Veneroloji
dc.relation.journalTürkderm-Türk Dermatoloji ve Zührevi Hastalıklar Arşivi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPsoriasis
dc.subjectPropylthiouracil
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectDermatology
dc.titleThe effects of topical prophylthiouracyl in plaque type psoriasis: A prospective, double-blind, placebo-controlled study
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dermatoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Patoloji Ana Bilim Dalı
relation.isAuthorOfPublication3a2758ac-215f-4821-ac4e-c5c751cd298b
relation.isAuthorOfPublication80df1863-762d-4cc1-9313-2d77d9e79ff8
relation.isAuthorOfPublication5bd3accb-bb59-411b-8d6c-46d06d35b5a4
relation.isAuthorOfPublication.latestForDiscovery3a2758ac-215f-4821-ac4e-c5c751cd298b

Files